Search

Displaying results 3631 - 3640 of 10000 in total
  1. Drug

    VP025

    go.drugbank.com/drugs/DB05133
    Experimental

    VP025 may inhibit immune system activation and protect motoneurons from injury. … It also shows the ability to reduce inflammation across the blood-brain barrier and improve correlates of memory and learning function.

  2. Drug

    Samidorphan

    go.drugbank.com/drugs/DB12543
    ApprovedInvestigational

    by Alkermes Inc. … [A235638, A235643] Samidorphan was first approved as a variety of fixed-dose combination tablets with [olanzapine] by the FDA on May 28, 2021, and is currently marketed under the trademark LYBALVI™

    Categories: olanzapine and samidorphan, Diazepines, Oxazepines, Thiazepines and Oxepines
  3. Drug

    SGS-742

    go.drugbank.com/drugs/DB05010
    Investigational

    SGS-742 has been used in trials studying the treatment of Seizures and Metabolic Disease.

  4. Drug

    Elivaldogene autotemcel

    go.drugbank.com/drugs/DB16746
    Approved

    It was approved by the European Commission in July 2021 under the market name Skysona, and was later withdrawn in November 2021 at the request of the marketing-authorization holder. … Without sufficient levels of functional ALDP, VLCFAs accumulate in the body leading to inflammation and destruction of myelin, which is an insulating layer and essential component of nerves.

    Categories: Cellular and Gene Therapy, Alimentary Tract and Metabolism
  5. Drug

    Grepafloxacin

    go.drugbank.com/drugs/DB00365
    ApprovedWithdrawn

    Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States … Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections.

  6. Drug

    MK-2748

    go.drugbank.com/drugs/DB15371
    Investigational

    MK-2748 is under investigation in clinical trial NCT01593735 (A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)).

  7. Target

    Serine/threonine-protein kinase mTOR

    go.drugbank.com/bio_entities/BE0002386
    TargetHumans

    As part of the mTORC2 complex, MTOR transduces signals from growth factors to pathways involved in proliferation, cytoskeletal organization, lipogenesis and anabolic output (PubMed:15268862, PubMed:15467718 … In response to growth factors, mTORC2 phosphorylates and activates AGC protein kinase family members, including AKT (AKT1, AKT2 and AKT3), PKC (PRKCA, PRKCB and PRKCE) and SGK1 (PubMed:15268862, PubMed

    Synonyms: Rapamycin and FKBP12 target 1
  8. Drug

    Alprostadil

    go.drugbank.com/drugs/DB00770
    ApprovedInvestigational

    This drug causes vasodilation by directly affecting vascular and ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth. … In 1996, the FDA approved the use of alprostadil, administered either with an intracavernosal injection or an intraurethral suppository, for the treatment of erectile dysfunction, and it is used in men

    Categories: Genito Urinary System and Sex Hormones
  9. Drug

    Almotriptan

    go.drugbank.com/drugs/DB00918
    Approved

    It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that cause pain, nausea, and other symptoms

    Categories: Serotonin-1b and Serotonin-1d Receptor Agonist
  10. Drug

    Lobeglitazone

    go.drugbank.com/drugs/DB09198
    Investigational

    Lobeglitazone is an antidiabetic medication from the thiazolidinedione class of drugs. … Lobeglitazone was approved by the Ministry of Food and Drug Safety (South Korea) in 2013, and is being monitored by postmarketing surveillance until 2019.

    Categories: Alimentary Tract and Metabolism, metformin and lobeglitazone